|
Steve Worland Ph.D. joined Anadys as Chief Scientific Officer in 2001. In October 2004 he was promoted to Executive Vice President Head of Research and Development. In December 2005 Dr. Worland was named Executive Vice President Pharmaceuticals. In June 2006 he was promoted to President Pharmaceuticals. In his new position Dr. Worland will lead all of Anadys' strategic planning corporate development and research & development efforts. From 1999 to 2001 he was Vice President Head of Antiviral Research at Agouron Pharmaceuticals a Pfizer Company. Dr. Worland was at Agouron from 1988 through the acquisition of Agouron by Warner-Lambert in 1999 where he held various positions and responsibilities that culminated with him assuming global responsibility for anti-infective strategy as Vice President for Warner-Lambert. At Agouron Warner-Lambert and Pfizer Dr. Worland led teams responsible for discovery and clinical development in the areas of HIV HCV and Rhinovirus. Dr. Worland was a National Institutes of Health Postdoctoral Fellow in Molecular Biology at Harvard University from 1985 to 1988. He received his B.S. in Biological Chemistry from the University of Michigan and his Ph.D. in Chemistry from the University of California Berkeley. | 